Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: A US payer perspective

Value in Health

Volumn 14, Issue 8, 2011, Pages 1002-1009

  Park, Haesuk ^a   Rascati, Karen L ^a   Keith, Michael S ^b   Hodgkins, Paul ^b   Smyth, Michael ^b   Goldsmith, David ^c   Akehurst, Ron ^d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b SHIRE   (United States)

^c GUY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

cost effectiveness; end stage renal disease (ESRD); hyperphosphatemia; lanthanum carbonate; Markov model; sevelamer hydrochloride

Indexed keywords

LANTHANUM CARBONATE; PHOSPHORUS; SEVELAMER;

ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CROSSOVER PROCEDURE; DRUG DOSE INCREASE; HEALTH CARE COST; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LIFE YEARS SAVED; MAJOR CLINICAL STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

CARDIOVASCULAR DISEASES; CHELATING AGENTS; COST-BENEFIT ANALYSIS; CROSS-OVER STUDIES; DATABASES, FACTUAL; ECONOMICS, PHARMACEUTICAL; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MARKOV CHAINS; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); POLYAMINES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; UNITED STATES;

EID: 82955205855     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.05.043     Document Type: Article

References (48)

1. J. Wright, A. Hutchison Cardiovascular disease in patients with chronic kidney disease Vasc Health Risk Manag 5 2009 713 722
2. A.S. Levey, J.A. Beto, B.E. Coronado Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease Am J Kidney Dis 32 1998 853 906 (Pubitemid 28516321)
3. Renal Data System (USRDS) 2008 Annual Data Report 2008 Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease Bethesda, MD
4. Renal Data System (USRDS) 2009 Annual Data Report 2009 Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease Bethesda, MD
5. S.M. Moe, G.A. Block, J.B. Cannata-Andia KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder Kidney International 76 Suppl. 113 2009 S1 S130
6. S. Moe, T. Drueke, J. Cunningham Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 69 2006 1945 1953 (Pubitemid 43924257)
7. A. Covic, P. Kothawala, M. Bernal Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease Nephrol Dial Transplant 24 2009 1506 1523
8. H. Komaba, K. Moriwaki, I. Kamae Towards cost-effective strategies for treatment of chronic kidney disease-mineral and bone disorder in Japan Ther Apher Dial 13 Suppl. 1 2009 S28 S35
9. G.A. Block, P.S. Klassen, J.M. Lazarus Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2004 2208 2218 (Pubitemid 39031360)
10. G.A. Block, T.E. Hulbert-Shearon, N.W. Levin, F.K. Port Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 1998 607 617
11. F. Tentori, M.J. Blayney, J.M. Albert Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 52 2008 519 530
12. B. Kestenbaum, J.N. Sampson, K.D. Rudser Serum phosphate levels and mortality risk among people with chronic kidney disease J Am Soc Nephrol 16 2005 520 528 (Pubitemid 41725150)
13. A.J. Hutchison Oral phosphate binders Kidney Int 75 2009 906 914
14. G. Eknoyan, N.W. levin K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 Suppl. 3 2003 S1 S201
15. I.A. Mohammed, A.J. Hutchison Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate Ther Clin Risk Manag 4 2008 887 893
16. J. Uribarri Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake Semin Dial 20 2007 295 301
17. J. Uribarri, M.S. Calvo Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 16 2003 186 188 (Pubitemid 37363217)
18. S.M. Sprague A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate Curr Med Res Opin 23 2007 3167 3175
19. G.M. Chertow, P. Raggi, S. Chasan-Taber Determinants of progressive vascular calcification in haemodialysis patients Nephrol Dial Transplant 19 2004 1489 1496 (Pubitemid 38786743)
20. G.A. Block, D.M. Spiegel, J. Ehrlich Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis Kidney Int 68 2005 1815 1824 (Pubitemid 43169927)
21. A. Barton Pai, T.A. Conner, C.R. McQuade Therapeutic use of the phosphate binder lanthanum carbonate Expert Opin Drug Metab Toxicol 5 2009 71 81
22. M.J. Taylor, H.A. Elgazzar, S. Chaplin An economic evaluation of sevelamer in patients new to dialysis Curr Med Res Opin 24 2008 601 608 (Pubitemid 351294410)
23. K.F. Huybrechts, J.J. Caro, D.A. Wilson, J.A. O'Brien Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis Value Health 8 2005 549 561 (Pubitemid 41741815)
24. B. Manns, S. Klarenbach, H. Lee Economic evaluation of sevelamer in patients with end-stage renal disease Nephrol Dial Transplant 22 2007 2867 2878 (Pubitemid 350093448)
25. K.F. Huybrechts, J.J. Caro, J.A. O'Brien Prevention and Management of Hyperphosphatemia with Sevelamer in Canada: Health and Economic Consequences Value Health 12 2009 16 19
26. A. Brennan, R. Akehurst, S. Davis The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease Value Health 10 2007 32 41 (Pubitemid 46161093)
27. M. Pignone, S. Earnshaw, J.A. Tice Aspirin, statins, or both drugs for the premary prevention of coronary heart disease events in men: a cost-utility analysis Ann Intern Med 144 2006 326 336 (Pubitemid 46768187)
28. R. Ara, A. Pandor, I. Tumur Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model Am J Cardiovasc Drugs 8 2008 419 427
29. M.R. Gold, L.B. Russell Cost-effectiveness in health and medicine 1996 Oxford University Press New York
30. S.M. Sprague, E.A. Ross, S.D. Nath Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study Clin Nephrol 72 2009 252 258
31. Renal Data System (USRDS) 2002 Annual Data Report 2002 Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease Bethesda, MD
32. E. Deconinck, H. Miadi-Fargier, C.L. Pen, P. Brice Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation Pharmacoeconomics 28 2010 35 46
33. Information for Vermont Prescribers of Prescription Drugs FOSRENOL™ chewable tablets First Data Bank Inc http://www.shirepricing.com/Documents/ FOSRENOL-long-form.pdf [Accessed October 2009]
34. Y.W. Chiu, I. Teitelbaum, M. Misra Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients Clin J Am Soc Nephrol 4 2009 1089 1096
35. P. Kaul, P.W. Armstrong, P.A. Cowper Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction Am Heart J 149 2005 637 644
36. G. Nichol, E. Huszti, A. Birnbaum Cost-effectiveness of lay responder defibrillation for out-of-hospital cardiac arrest Ann Emerg Med 54 2009 226 235
37. Renal Data System (USRDS) 2005 Annual Data Report 2005 Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease Bethesda, MD
38. G.A. de Wit, P.G. Ramsteijn, F.T. de Charro Economic evaluation of end stage renal disease treatment Health Policy 44 1998 215 232 (Pubitemid 28345184)
39. K.C. Young, J.C. Teeters, C.G. Benesch Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator J Clin Hypertens (Greenwich) 11 2009 555 563
40. T.O. Tengs, T.H. Lin A meta-analysis of quality-of-life estimates for stroke Pharmacoeconomics 21 2003 191 200 (Pubitemid 36286663)
41. S. Spronk, J.L. Bosch, C. Ryjewski Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease PLoS One 3 2008 e3883 110
42. R.F. Nease, T. Kneeland, G.T. O'Connor Variation in patient utilities for outcome of the management of chronic stable angina JAMA 273 1995 1185 1190
43. J. Tsevat, L. Goldman, J.R. Soukup Stability of time-tradeoff utilities in survivors of myocardial infarction Med Decis Making 13 1993 161 165 (Pubitemid 23113453)
44. D. Coyle, R. Rodby, S. Soroka Cost-effetiveness of irbesartan 300mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective Clinical Therapeutics 29 2007 1508 1523 (Pubitemid 47354210)
45. A.H. Briggs Handling uncertainty in cost-effectiveness models Pharmacoeconomics 17 2000 479 500 (Pubitemid 30398806)
46. K.F. Huybrechts, J.J. Caro, G.M. London Modeling the implications of changes in vascular calcification in patients on hemodialysis Kidney Int 67 2005 1532 1538 (Pubitemid 40463132)
47. W.F. Finn, M.S. Joy A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis Curr Med Res Opin 21 2005 657 664 (Pubitemid 40695287)
48. A.J. Hutchison, M.E. Barnett, R. Krause Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment Nephron Clin Pract 110 2008 c15 c23